Post-Finasteride Syndrome: Symptoms, Evidence, and Current Research

Post-Finasteride Syndrome (PFS) refers to a constellation of adverse effects — primarily sexual, but also neuropsychological and physical — that continue, worsen, or first appear after men stop taking finasteride. It is clinically recognized, FDA-label documented, and actively researched. It is also controversial: its frequency is uncertain, its biological mechanisms are unproven, and there is currently no established treatment. This page presents the evidence fairly.

FDA Recognition

This 2012 FDA label update was the first formal regulatory acknowledgment that persistent sexual adverse effects occur in a subset of former finasteride users. The label was updated following review of post-marketing surveillance reports and published case series. This was a significant acknowledgment because it formally validated what patients had been reporting for years, despite the short-term trial data showing resolution of side effects upon discontinuation in most men.

Reported Symptoms

PFS symptoms reported across case series, registries, and patient-reported outcome studies include:

Sexual Symptoms (most commonly reported)

• Erectile dysfunction — often reported as qualitatively different from typical ED (reduced spontaneous erections, reduced rigidity)
• Decreased or absent libido
• Ejaculatory dysfunction (decreased volume, anorgasmia)
• Genital numbness or reduced penile sensitivity
• Penile shrinkage or atrophy (reported in case series; not confirmed in controlled studies)

Neuropsychological Symptoms

• Depression, anhedonia (inability to experience pleasure)
• Cognitive impairment (“brain fog”) — difficulty concentrating, memory problems
• Emotional blunting (reduced emotional range)
• Anxiety, panic attacks
• Suicidal ideation (noted in EMA 2019 review; led to European label update)

Physical Symptoms

• Gynecomastia
• Fatigue, reduced energy
• Muscle weakness or pain
• Joint pain

How Common Is PFS?

The honest answer: we don’t know with precision. No large, well-controlled epidemiological study has established the prevalence of persistent PFS symptoms in the general population of men who take finasteride.

• A 2020 study by Khera et al. found that among 787 men who completed a validated questionnaire, PFS-like persistent sexual symptoms were reported by a meaningful subset, but the study used a self-selected sample with known limitations
• The PFS Foundation patient registry has collected data from over 600 patients; this data documents the phenomenon but cannot establish population prevalence
• Estimates in the literature range from <1% to several percent of finasteride users — but these estimates are based on selected populations and carry significant uncertainty

The fact that PFS is uncommon relative to the large population of finasteride users does not diminish its severity or impact on affected individuals. It means that currently available data cannot answer the question “what is my individual risk of PFS” with precision.

Proposed Biological Mechanisms

Several hypotheses have been proposed to explain PFS. None has been definitively established in human studies:

• Neurosteroid disruption: DHT is a precursor to allopregnanolone, a positive allosteric modulator of GABA-A receptors. Finasteride’s suppression of DHT may reduce allopregnanolone levels, disrupting GABAergic neurotransmission involved in mood, cognition, and sexual function. Possible epigenetic persistence after stopping.
• Epigenetic androgen receptor dysregulation: Studies from Melcangi and colleagues have found epigenetic changes in androgen receptor gene expression in rats and in limited human samples after finasteride treatment. These changes could theoretically persist after the drug is cleared.
• Androgen receptor upregulation: Compensatory upregulation of androgen receptors during DHT suppression may lead to hypersensitivity to even normal DHT levels after stopping — a rebound over-response or persistent dysregulation.
• Peripheral nerve tissue effects: Finasteride and its neurosteroid targets are expressed in peripheral nerves and Schwann cells; disruption to these systems during treatment may affect genital sensation.

Current Research

PFS is an active research area. Key ongoing efforts as of 2026:

• The PFS Foundation (pfsfoundation.org) funds and coordinates PFS research, maintains a patient registry, and supports peer-reviewed publication of PFS data
• The PFSN (Post-Finasteride Syndrome Network) supports research into biomarkers for PFS
• Multiple academic research groups (including Boston University, University of Perugia under Melcangi) are investigating neurosteroid and epigenetic mechanisms

What Should You Do If You Think You Have PFS?

• See a physician — a urologist, endocrinologist, or psychiatrist with experience in sexual medicine. PFS symptoms overlap with those of other treatable conditions (hypogonadism, depression, anxiety, vascular ED) that warrant evaluation regardless of finasteride history
• Do not self-treat — testosterone supplementation, SSRIs, or other interventions should be medically supervised
• Report to FDA MedWatch — post-marketing adverse event reports are important for ongoing regulatory surveillance: fda.gov/safety/medwatch
• PFS Foundation: pfsfoundation.org — patient support resources and participation in ongoing research

Frequently Asked Questions

Is Post-Finasteride Syndrome a real condition?

Yes. PFS is recognized by the FDA (2012 label update), documented in peer-reviewed literature, and supported by biological plausibility (neurosteroid and epigenetic mechanisms). What remains uncertain is its frequency, its biological mechanism (no single explanation has been conclusively validated in human studies), and any effective treatment. The fact that PFS is rare relative to the total population of finasteride users does not mean it doesn’t exist or that it is “just psychological” — the available evidence does not support dismissing it.

Does stopping finasteride reduce PFS risk?

This is not established. The conventional assumption was that stopping finasteride would resolve its side effects — and in most men, it does. But PFS by definition refers to symptoms that persist after stopping. Whether stopping sooner (at the first sign of side effects) versus later reduces PFS risk is not known from controlled data. Men experiencing side effects on finasteride should discuss options with their physician promptly rather than waiting.

Sources

• U.S. FDA. Drug Safety Communication: Propecia and Proscar label update on persistent sexual side effects. April 11, 2012.
• Khera M, et al. “Post-Finasteride Syndrome: a snapshot of the clinical evidence and a look forward.” Urology. 2020.
• Melcangi RC, et al. “Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.” J Steroid Biochem Mol Biol. 2017;171:229–235.
• European Medicines Agency. “EMA updates finasteride labels to add depression and suicidal ideation as side effects.” Press Release, 2019.